117 related articles for article (PubMed ID: 3557254)
1. [Omeprazole and peptic ulcer. Profile of a new active agent].
Müller P; Dammann HG; Simon B
Fortschr Med; 1987 Jan; 105(2):35-8. PubMed ID: 3557254
[No Abstract] [Full Text] [Related]
2. [Omeprazole. A new substance for inhibiting acid production].
Uhl D
Med Monatsschr Pharm; 1990 Feb; 13(2):34-7. PubMed ID: 2179691
[No Abstract] [Full Text] [Related]
3. Omeprazole.
Med Lett Drugs Ther; 1990 Mar; 32(813):19-21. PubMed ID: 2179694
[No Abstract] [Full Text] [Related]
4. [Indications and use of omeprazole in esophago-gastro-duodenal diseases].
Martín de Argila C; Boixeda de Miquel D; Moreira Vicente V; García Plaza A
Rev Clin Esp; 1999 Nov; 199(11):729-39. PubMed ID: 10638238
[No Abstract] [Full Text] [Related]
5. Omeprazole: a new drug for the treatment of acid-peptic diseases.
Falk GW
Cleve Clin J Med; 1991; 58(5):418-27. PubMed ID: 1934456
[TBL] [Abstract][Full Text] [Related]
6. [Possibilities of the use of present-day antisecretory preparation omeprazole].
Degtiareva II; Semeunovich S; Kharchenko NV; Petrovich S; Gaĭsenko AV; Egorova IT
Klin Med (Mosk); 1994; 72(6):38-40. PubMed ID: 7898006
[No Abstract] [Full Text] [Related]
7. [Omeprazole].
Isal JP
Gastroenterol Clin Biol; 1987 Nov; 11(11):768-80. PubMed ID: 3322924
[No Abstract] [Full Text] [Related]
8. Treatment of patients with Zollinger-Ellison syndrome.
Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
[TBL] [Abstract][Full Text] [Related]
9. [Omeprazole. Its pharmacology and therapeutic efficacy].
Protzer U; Holtermüller KH
Dtsch Med Wochenschr; 1993 Feb; 118(7):230-9. PubMed ID: 8440164
[No Abstract] [Full Text] [Related]
10. [What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Arnold R
Fortschr Med; 1994 Jan; 112(1-2):44-5. PubMed ID: 8144120
[No Abstract] [Full Text] [Related]
11. Drug therapy of peptic ulcer disease.
Ching CK; Lam SK
Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
[TBL] [Abstract][Full Text] [Related]
12. The clinical safety of omeprazole.
Sölvell L
Scand J Gastroenterol Suppl; 1989; 166():106-10; discussion 111-3. PubMed ID: 2690327
[TBL] [Abstract][Full Text] [Related]
13. Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpepsinogenemia I in an infant.
De Giacomo C; Fiocca R; Villani L; Licardi G; Scotta MS; Solcia E
J Pediatr; 1990 Dec; 117(6):989-93. PubMed ID: 2246706
[No Abstract] [Full Text] [Related]
14. [Substituted benzimidazoles--a new dimension in ulcer therapy?].
Fimmel CJ; Blum AL
Wien Klin Wochenschr; 1984 Feb; 96(4):149-53. PubMed ID: 6324498
[TBL] [Abstract][Full Text] [Related]
15. Omeprazole.
Friedman G
Am J Gastroenterol; 1987 Mar; 82(3):188-91. PubMed ID: 3548325
[No Abstract] [Full Text] [Related]
16. [25 years of gastric acid blockers].
Lamers CB
Ned Tijdschr Geneeskd; 1999 Dec; 143(50):2501-4. PubMed ID: 10627749
[TBL] [Abstract][Full Text] [Related]
17. Criteria for use of omeprazole in adult inpatients and outpatients.
Lajoie C
Clin Pharm; 1992 Feb; 11(2):177-9. PubMed ID: 1551300
[No Abstract] [Full Text] [Related]
18. [Risk for developing tumors in therapy with the proton pump inhibitor omeprazole].
Eissele R; Arnold R
Versicherungsmedizin; 1993 Aug; 45(4):126-9. PubMed ID: 8379045
[TBL] [Abstract][Full Text] [Related]
19. The clinical safety of omeprazole.
Sölvell L
Digestion; 1990; 47 Suppl 1():59-63; discussion 76. PubMed ID: 2093017
[TBL] [Abstract][Full Text] [Related]
20. [Omeprazole in peptic ulcer--pros and cons].
Stasiewicz J
Wiad Lek; 1986 Jun; 39(11):765-71. PubMed ID: 3535259
[No Abstract] [Full Text] [Related]
[Next] [New Search]
